313348-27-5 | Regadenoson

Packsize	Purity	Availability	Price	Discounted Price
1mg	≥98%	in stock	$57.00	$40.00
5mg	98%	in stock	$82.00	$57.00
25mg	98%	in stock	$157.00	$110.00
100mg	98%	in stock	$405.00	$284.00

Description

• Catalog Number: AF68226
• Chemical Name: Regadenoson
• CAS Number: 313348-27-5
• Molecular Formula: C15H18N8O5
• Molecular Weight: 390.3540
• MDL Number: MFCD09832544
• SMILES: OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1nc(nc2N)n1ncc(c1)C(=O)NC

Computed Properties

• Complexity: 587
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 28
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 5
• Rotatable Bond Count: 4
• XLogP3: -1.5

Literature

• Adenosine A2A receptor as a drug discovery target.

  Journal of medicinal chemistry 20140508

• Safety and feasibility of regadenoson use for suboptimal heart rate response during symptom-limited standard Bruce exercise stress test.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20121001

• Comparison and effectiveness of regadenoson versus dipyridamole on stress electrocardiographic changes during positron emission tomography evaluation of patients with hypertrophic cardiomyopathy.

  The American journal of cardiology 20121001

• Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.

  JACC. Cardiovascular imaging 20121001

• The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study.

  The international journal of cardiovascular imaging 20120801

• A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120801

• Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. 'The ASSUAGE trial'.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120601

• The role of the A2a receptor agonist, regadenoson, in modulating hepatic artery flow in the porcine small-for-size liver graft.

  The Journal of surgical research 20120501

• Seizures associated with regadenoson: a case series.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120401

• Detection of coronary stenosis with myocardial contrast echocardiography using regadenoson, a selective adenosine A2A receptor agonist.

  European heart journal cardiovascular Imaging 20120401

• A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120401

• Selective adenosine agonists and myocardial perfusion imaging.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120201

• Selective action of metoprolol to attenuate regadenoson-induced tachycardia in conscious dogs.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120201

• Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor.

  Journal of medicinal chemistry 20120112

• Coronary vasospasm during a regadenoson stress test.

  Cardiology journal 20120101

• Regadenoson.

  Journal of postgraduate medicine 20120101

• Quantitative three-dimensional evaluation of myocardial perfusion during regadenoson stress using multidetector computed tomography.

  Journal of computer assisted tomography 20120101

• A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20111201

• Rapid detection of coronary artery stenoses with real-time perfusion echocardiography during regadenoson stress.

  Circulation. Cardiovascular imaging 20111101

• Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET.

  European journal of nuclear medicine and molecular imaging 20111001

• Ischemic electrocardiogram during pharmacologic stress with regadenoson.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20111001

• Clinical utility of regadenoson for assessing fractional flow reserve.

  JACC. Cardiovascular interventions 20111001

• The crux of maximum hyperemia: the last remaining barrier for routine use of fractional flow reserve.

  JACC. Cardiovascular interventions 20111001

• Adenosine receptor signaling modulates permeability of the blood-brain barrier.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110914

• Targeting iNKT cells for the treatment of sickle cell disease.

  Clinical immunology (Orlando, Fla.) 20110801

• Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20110801

• Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20110801

• Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20110801

• Development of asystole requiring cardiac resuscitation after the administration of regadenoson in a patient with pulmonary fibrosis receiving n-acetylcysteine.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20110501

• Safety of regadenoson in patients with end-stage liver disease.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20110201

• Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20110201

• Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20101001

• Advances in pharmacologic stress agents: focus on regadenoson.

  Journal of nuclear medicine technology 20100901

• The emerging role of the selective A2A agonist in pharmacologic stress testing.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20100601

• Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome.

  The American journal of cardiology 20100315

• Regadenoson.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-sestaMIBI biodistribution and kinetics.

  JACC. Cardiovascular imaging 20091001

• Connectivity of radiotracers to vasodilators is thallium the missing link?

  JACC. Cardiovascular imaging 20091001

• Regadenoson: a new myocardial stress agent.

  Journal of the American College of Cardiology 20090922

• Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.

  JACC. Cardiovascular imaging 20090801

• Current advances in vasodilator pharmacological stress perfusion imaging.

  Seminars in nuclear medicine 20090501

• Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus.

  American heart journal 20090401

• Current methods of pharmacologic stress testing and the potential advantages of new agents.

  Journal of nuclear medicine technology 20090301

• The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20090101

• Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20090101

• An example of the clinical selectivity of regadenoson for the A2a adenosine receptor.

  The American heart hospital journal 20090101

• Regadenoson, a novel pharmacologic stress agent for use in myocardial perfusion imaging, does not have a direct effect on the QT interval in conscious dogs.

  Journal of cardiovascular pharmacology 20081101

• FDA approves pharmacologic stress agent.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080515

• New stress test agents reduce adverse effects.

  JAMA 20080514

• Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results.

  JACC. Cardiovascular imaging 20080501

• Lessons from the development of new adenosine A2A receptor agonists.

  JACC. Cardiovascular imaging 20080501

• Regadenoson in the detection of coronary artery disease.

  Vascular health and risk management 20080401

• Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial.

  Journal of the American College of Cardiology 20080122

• Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial).

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20080101

• Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20080101

• Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function.

  Journal of clinical pharmacology 20070701

• Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20070701

• Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist.

  Journal of cardiovascular pharmacology 20070601

• Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20070101

• Adenosine receptors as therapeutic targets.

  Nature reviews. Drug discovery 20060301

• Advances in pharmacologic agents in imaging: new A2A receptor agonists.

  Current cardiology reports 20060301

• Regadenoson (CV Therapeutics/Astellas).

  Current opinion in investigational drugs (London, England : 2000) 20060301

• Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats.

  The Journal of pharmacology and experimental therapeutics 20060201

• A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.

  Clinical pharmacokinetics 20060101

• Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging.

  Journal of the American College of Cardiology 20051206

• 2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists.

  Journal of medicinal chemistry 20040909

• The future of pharmacologic stress: selective A2A adenosine receptor agonists.

  The American journal of cardiology 20040722

• Comparative profile of vasodilation by CVT-3146, a novel A2A receptor agonist, and adenosine in conscious dogs.

  The Journal of pharmacology and experimental therapeutics 20031001

• Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging.

  Journal of cardiovascular pharmacology 20030101

• Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.

  Bioorganic & medicinal chemistry letters 20021021

• Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists.

  The Journal of pharmacology and experimental therapeutics 20010701